Experts preview ASTRO 2026 presentations to watch, including those on SOFT Preop, PSMAgRT, radiosurgery for depression, and AI tools for patient safety.
|Articles|January 1, 1999
- ONCOLOGY Vol 13 No 1
- Volume 13
- Issue 1
Varian Creates Patient Education Web Site
Varian has created a new patient education Internet web site containing information on cancer radiotherapy treatments.
Advertisement
Varian has created a new patient education Internet web site containing information on cancer radiotherapy treatments. The site includes information from the National Cancer Institute and leading cancer treatment centers. Varians cancer patient education web site is located at
Articles in this issue
over 27 years ago
Follow-up Essential for Positive Home HIV Test Resultsover 27 years ago
FDA Treads Delicate Line Between Safety and Speedover 27 years ago
Estrogen May Reduce Colorectal Cancer Risk in Postmenopausal Womenover 27 years ago
Sentinel Lymph Node Mapping in Breast CancerAdvertisement
Related to this article
Data from the phase 3 MK-3475A-D77 trial support the Japanese approval of subcutaneous pembrolizumab and berahyaluronidase alfa.
David R. Gandara, MD, explains what makes KRAS G12C biologically distinct from other KRAS subtypes in NSCLC immunotherapy response.
Xiuning Le, MD, PhD, weighs sevabertinib against zongertinib and trastuzumab deruxtecan in HER2-mutant non–small cell lung cancer.
A prospective, multicenter study found that a blood-based miRNA assay combined with CA19-9 improved early detection of pancreatic ductal adenocarcinoma.
Final 5-year IMCgp100-202 data show tebentafusp improved OS vs investigator’s choice in untreated HLA-A*02:01–positive metastatic uveal melanoma.
The FDA granted platform technology designation to the immunotherapeutic platform for use in HPV-positive cancers such as head and neck, cervical, and anal.
An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
PANXEON Liquid Biopsy Demonstrates Potential for Detecting Early Pancreatic Cancer
3
Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera
4
AdenoVerse Platform Receives FDA Designation for HPV-Associated Cancers
5